Showing 1361-1370 of 1610 results for "".
- New Software Update Expands Capabilities of the OD-OS Navilas 577shttps://modernod.com/news/new-software-update-expands-capabilities-of-the-od-os-navilas-577s/2476754/OD-OS has released a new software update for its Navilas 577s. With a new multimodal “export wizard,” retina specialists can generate high resolution images of their treatments in different configurations. This allows for advanced, transparent documentation for all purposes and record
- OD-OS Releases Intuitive Iridotomy Treatment with the Navilas 577s Retina Laserhttps://modernod.com/news/od-os-releases-intuitive-iridotomy-treatment-with-the-navilas-577s-retina-laser/2479613/OD-OS has released a software update for its Navilas 577s retinal laser system (version 3.5) that incorporates a new intuitive anterior segment treatment mode for Laser Peripheral Iridotomy (LPI). The new LPI treatment mode supports the therapy of narrow-angle glaucoma and thus can contribute to
- J&J Expands Availability of Tecnis Odyssey PC-IOLhttps://modernod.com/news/jjs-tecnis-odyssey-pc-iol-now-fully-commercially-available/2482462/Johnson & Johnson announced the expansion of its Tecnis Odyssey presbyopia-correcting IOL (PC-IOL) across the US. The Tecnis Odyssey IOL offers patients continuous full-range vision, reducing the need for glasses by providing clear vision from far to near and everything in between[3,6]. Built
- EU Greenlights J&J’s Coronavirus Vaccinehttps://modernod.com/news/eu-greenlights-jjs-coronavirus-vaccine/2478966/The European Commission granted a conditional marketing authorization for Johnson & Johnson’s single-dose COVID-19 vaccine Ad26.COV2.S in people 18 years of age and over. The decision comes just hours after the European Medicines Agency (EMA) gave its backing following a review of ̶
- J&J Looking to Enroll 60,000 Participants in Coronavirus Vaccine Trialhttps://modernod.com/news/jj-looking-to-enroll-60000-participants-in-coronavirus-vaccine-trial/2478185/A phase 3 trial Johnson & Johnson is planning to get under way in September to test its coronavirus vaccine candidate Ad26.COV2.S is looking to recruit up to 60,000 participants globally, the company confirmed Thursday. The targeted enrollment, first reported on the ClinicalTrials.gov databas
- J&J Vaccine Protects Monkeys From Covid With Single Shothttps://modernod.com/news/jj-vaccine-protects-monkeys-from-covid-with-single-shot/2478099/Johnson & Johnson’s experimental coronavirus vaccine protected a group of macaques with a single shot in an early study, prompting the U.S. drugmaker to start trials in humans this month, according to a Bloomberg
- Perry J. Sternberg Joins Sydnexis as Chief Executive Officerhttps://modernod.com/news/perry-j-sternberg-joins-sydnexis-as-chief-executive-officer/2482358/Sydnexis has announced the appointment of Perry J. Sternberg as Chief Executive Officer and a member of the Board of Directors. Mr. Sternberg is a pharma/biotech executive with more than 30 years in the industry and 15 years in eye care. Immediately prior to joining Sydnexis,
- Iveric Bio Receives Permanent J-code for GA Treatment Izervayhttps://modernod.com/news/iveric-bio-receives-permanent-j-code-for-ga-treatment-izervay/2482181/Iveric Bio, a subsidiary of Astellas, announced that CMS has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPS) J-code for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macula
- Edward J. Holland, MD, to Join Alcon as Member of the Research and Development Teamhttps://modernod.com/news/edward-j-holland-md-to-join-alcon-as-member-of-the-research-and-development-team/2481000/Alcon announced that Edward J. Holland, MD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Holland is a thought leader in ophthalmology, specializing in the field of cornea and the ocular surface. He will serve as an enterprise Senior Scientifi
- TearClear Appoints Robert J. Dempsey Chief Executive Officerhttps://modernod.com/news/tearclear-appoints-robert-j-dempsey-chief-executive-officer/2477596/TearClear announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the only pharmaceutical company to administer preservative free eye drops to the ocular surface, that are preserved safely prior to dosing, according to a company news release. <